Resurrecting the House Call
New at-home strategies for hematologic conditions offer improved outcomes and patient satisfaction
Physician home visits have become a thing of the past: Nearly a century ago, house calls made up 40 percent of U.S. doctors’...
Online Exclusives
Medicare Poised to Cover CAR T-Cell Therapy
Medicare may soon offer coverage of chimeric antigen receptor (CAR) T-cell therapy for patients with cancer, but with considerable restrictions that aim to rein...
PBM Execs Testify Before Congress About High Drug Prices
It was pharmacy benefit managers’ (PBMs’) turn to testify before Congress during an April 9 Senate Finance Committee hearing as part of an ongoing...
News
From the Blood Journals
Venetoclax Plus Obinutuzumab Confers High MRD-Negative Rates in CLL
Results from a phase Ib study demonstrated that the combination of the BCL2 inhibitor venetoclax with the anti-CD20 monoclonal antibody obinutuzumab was safe and...
Evaluating Thalidomide-Cyclophosphamide-Prednisone for Idiopathic Multicentric Castleman Disease
An oral combination of thalidomide, cyclophosphamide, and prednisone (TCP) induced durable tumor and symptomatic response rates in nearly half of patients with newly diagnosed...
Multimedia
Pulling Back the Curtain: Lukas Wartman, MD
In more from our interview with Lukas Wartman, MD, he discusses his decision to go into medicine and his life as a doctor and...
Pulling Back the Curtain: Dan Pollyea, MD, MS
In more from our interview with Dan Pollyea, MD, MS, he shares what he learned from growing up watching his father practice medicine and the simple...
Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism
Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...
Ravulizumab: A New Treatment Option for PNH?
Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
On Location
Are CAR T-Cell Therapies Moving to Hodgkin Lymphoma?
Results from two studies presented at the 2019 Transplantation & Cellular Therapy Meetings suggest that...
Beta-Thalassemia Gene Therapy Continues to Show Efficacy in Longer-Term Follow-up
Updated results from the phase I/II HGB-204 and HGB-207 trials indicated that several patients with...
Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas
Chimeric antigen receptor (CAR) T-cell therapies engineered to recognize and destroy CD19 antigens on the...
Post-Transplant Ixazomib Maintenance Prolongs Survival in Newly Diagnosed Myeloma
For patients with newly diagnosed multiple myeloma (MM) who relapse following autologous hematopoietic cell transplantation...
A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres?
A study of patients with bone marrow failure (BMF) and short telomeres found that a...
Alemtuzumab Plus Myeloablative Conditioning Reduces Post-Transplant GVHD Risk
For younger patients with sickle cell disease (SCD) who are eligible for a hematopoietic cell...
Latest Headlines
ASH Directions
Seventh Edition of ASH-SAP Coming Soon, CDC Responds to ASH’s Concerns About Opioid Guidelines
CDC Clarifies Opioid Prescribing Guideline at Urging of Hematology and Oncology GroupsHematologists, especially sickle cell disease (SCD) specialists, are welcoming a recent clarification from...
ASH Expands Global Initiative, Awards Research Award to Minority Scholar
ASH Expands Global Initiative With Research Award for Hematologists Outside North America
The American Society of Hematology (ASH) Global Research Award was established in 2018...
Remembering Arthur Rosenberg, Dorothy Tuan Lo, and more
Remembering Arthur Rosenberg (1935 – 2018)
Arthur Rosenberg, MD, FRCPC, a former chief of hematology at the Jewish General Hospital (JGH) in Montreal, Quebec, passed...
Remembering Francesco Lo Coco, NYU Langone Health to Establish Center for Blood Cancers, and...
Remembering Francesco Lo Coco (1955 – 2019)
Francesco Lo Coco, MD, a renowned leukemia researcher and pioneer of targeted therapy, passed away on March 3,...
Boston Children’s Hospital Receives $1.5 million for SCD Research, Fred Hutch Names New Endowed...
Weill Cornell Researchers Awarded $9 Million for Lymphoma Research
The National Cancer Institute (NCI) awarded a five-year, $9-million Program Project Grant (P01) to Weill Cornell...
Resurrecting the House Call
New at-home strategies for hematologic conditions offer improved outcomes and patient satisfaction
Physician home visits have become a thing of the past: Nearly a century...
Reader Beware: Interpreting Clinical Trial Data
Numbers don’t lie – except when people cause them to.
With an abundance of scientific research being presented and published, many health-care practitioners rely on...
Planes, Trains, and VTEs
Simple recommendations can help mitigate risk for travel-related blood clots
In November 2011, hematologist Suely Rezende, MD, PhD, deplaned from a flight from Lisbon to...
